Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023

Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024

Published:2024-02-01 Issue:4 Volume:73 Page:77-83
ISSN:0149-2195
Container-title:MMWR. Morbidity and Mortality Weekly Report
language:
Short-container-title:MMWR Morb. Mortal. Wkly. Rep.

Author:

Link-Gelles Ruth,Ciesla Allison Avrich,Mak Josephine,Miller Joseph D.,Silk Benjamin J.,Lambrou Anastasia S.,Paden Clinton R.,Shirk Philip,Britton Amadea,Smith Zachary R.,Fleming-Dutra Katherine E.

Publisher

Centers for Disease Control MMWR Office

Reference9 articles.

1. Use of updated COVID-19 vaccines 2023–2024 formula for persons aged ≥6 months: recommendations of the Advisory Committee on Immunization Practices—United States, September 2023.;Regan;MMWR Morb Mortal Wkly Rep,2023

2. Spike gene target amplification in a diagnostic assay as a marker for public health monitoring of emerging SARS-CoV-2 variants—United States, November 2021–January 2023.;Scobie;MMWR Morb Mortal Wkly Rep,2023

3. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5– and XBB/XBB.1.5–related sublineages among immunocompetent adults—Increasing Community Access to Testing program, United States, December 2022–January 2023.;Link-Gelles;MMWR Morb Mortal Wkly Rep,2023

4. Validation of reduced S-gene target performance and failure for rapid surveillance of SARS-CoV-2 variants.;Clark;PLoS One,2022

5. Virological characteristics of the SARS-CoV-2 JN.1 variant.;Kaku;Lancet Infect Dis,2024

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines;Expert Review of Vaccines;2024-09-13

2. Immune evasiveness of SARS-CoV-2 variants and vaccine selection;The Lancet Infectious Diseases;2024-09

3. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study;The Lancet Infectious Diseases;2024-09

4. First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial;eBioMedicine;2024-09

5. SARS-CoV-2 JN.1 variant: a short review;Monaldi Archives for Chest Disease;2024-08-30